Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of “Moderate Buy” from Analysts

Septerna, Inc. (NASDAQ:SEPN) has been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $45.8889.

A number of research analysts recently issued reports on SEPN shares. Stifel Nicolaus started coverage on shares of Septerna in a report on Friday, May 1st. They set a “buy” rating and a $43.00 price objective for the company. Guggenheim decreased their price target on shares of Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a report on Wednesday, July 1st. Raymond James Financial raised their price objective on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research note on Monday, June 8th. Truist Financial boosted their target price on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Septerna in a report on Wednesday, July 1st.

Septerna Trading Up 1.5%

Shares of Septerna stock opened at $34.98 on Tuesday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -43.18 and a beta of 2.29. The firm’s 50-day moving average price is $33.72 and its two-hundred day moving average price is $28.67. Septerna has a 1-year low of $10.62 and a 1-year high of $38.04.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The business had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. As a group, equities research analysts predict that Septerna will post -1.59 EPS for the current year.

Insider Transactions at Septerna

In other Septerna news, insider Samira Shaikhly sold 11,798 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the sale, the insider directly owned 793 shares in the company, valued at $23,837.58. This represents a 93.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Daniel D. Long sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the sale, the senior vice president directly owned 96,412 shares in the company, valued at $3,423,590.12. The trade was a 13.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 44,494 shares of company stock worth $1,469,391. 5.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Group One Trading LLC raised its stake in shares of Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares during the last quarter. Global Retirement Partners LLC acquired a new position in Septerna during the fourth quarter worth $35,000. Russell Investments Group Ltd. acquired a new position in Septerna during the 3rd quarter worth $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Septerna during the fourth quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Septerna during the fourth quarter worth approximately $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.